Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-2018344827-A1
Application number	US-201816100498-A
Country	US
Kind code	A1
Filing date	Aug 10, 2018
Priority date	Aug 5, 2015
Publication date	Dec 6, 2018
Grant date	—

Abstract

A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

First claim

1 . A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells which present a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49),
wherein said cancer is selected from the group consisting of prostate cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer (CRC), urinary bladder cancer, non-small cell lung cancer, kidney cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, esophageal cancer, brain cancer, and gastric cancer.

2 . The method of claim 1 , wherein the T cells are autologous to the patient.

3 . The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4 . The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5 . The method of claim 1 , wherein the activated T cells are expanded in vitro.

6 . The method of claim 1 , wherein the peptide is in a complex with an MHC class I molecule.

7 . The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

8 . The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

9 . The method of claim 8 , wherein the antigen presenting cell is infected with recombinant virus expressing the peptide.

10 . The method of claim 9 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

11 . The method of claim 8 , wherein the contacting is in vitro.

12 . The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.

13 . The method of claim 12 , wherein the composition further comprises an adjuvant.

14 . The method of claim 13 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

15 . The method of claim 1 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49).

16 . The method of claim 15 , wherein the immune response comprises a cytotoxic T cell response.

17 . The method of claim 1 , wherein the cancer is prostate cancer.

18 . A method of eliciting an immune response in a patient who has prostate cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer (CRC), urinary bladder cancer, non-small cell lung cancer, kidney cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, esophageal cancer, brain cancer, and/or gastric cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide consists of the amino acid sequence of SLFHPEDTGQV (SEQ ID NO: 49), thereby inducing a T cell response to the prostate cancer, small cell lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer (CRC), urinary bladder cancer, non-small cell lung cancer, kidney cancer, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), ovarian cancer, esophageal cancer, brain cancer, and/or gastric cancer.

19 . The method of claim 18 , wherein the T cell response is a cytotoxic T cell response.

20 . The method of claim 18 , wherein the cancer is prostate cancer.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Müller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C07K14/4748 Primary

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title